Advanced Therapeutics in Rheumatoid Arthritis (RA)
Recruiting now Phase 4 NCT03976245
Run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · for 18 and older · All sexes
What this study is about
This study will evaluate the retention rates of two advanced therapies, Tumour Necrosis Factor (TNF) and Janus kinase inhibitor (JAK) in the treatment of adults with Rheumatoid Arthritis (RA) over a two year period. It will also examine the ability to embed a clinical trial in a clinical situation using an electronic medical record (EMR).
Who can join (things the study team will check)
✅ You may be able to join if…
- patients with RA who meet criteria for obtaining an advanced therapeutic through usual care
- active RA with 5 or more swollen joints
- seropositive
- presence of erosions
- failure of methotrexate and hydroxychloroquine and sulfasalazine
- failure of Leflunomide -> or equal to 18 years
- able to provide consent
- able to attend usual follow up visits
🚫 You may not be able to join if…
- no contraindication to etanercept or tofacitinib
- active serious infection
- active Tuberculosis
- multiple sclerosis
- current cancer
- lymphoma ever
- previous use of an advanced therapeutic (biologic or JAK kinase inhibitor)
- less than 18 years of age
- unable to provide consent
Where this trial is running
- Rheumatology Clinic, St. Joseph's Health Care, London, Ontario, Canada
Who to contact
Janet E Pope, MD MPH · 519 646-6000 · janet.pope@sjhc.london.on.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT03976245.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.